AI Conductor operates as an orchestration layer across PhaseV’s vertical AI platform.

Six studies in collaboration with Mayo Clinic confirm the UltraSight™ Echosystem enables non-expert clinicians to ...

Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals ...

The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.

Brenig Therapeutics, Inc. (Brenig), a clinical-stage biotechnology company advancing small-molecule therapies for neurologic diseases, today announced that Tien Dam, MD, Chief Medical Officer, will ...

Led by researchers at NDORMS as part of the Data Analysis and Real World Interrogation Network (DARWIN EU) initiative, a new ...

A powerful new real-world data platform could transform how scientists predict and understand Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD), reports a new study at Columbia ...

TOS-358 is an oral, highly selective, pan-mutant, covalent PI3Ka inhibitor that achieves >95% continuous target engagement for deep and durable inhibition of PI3K-AKT signaling which is required for ...

ClinCapture announces AI-powered clinical trial build tech that automates study configuration, and advances intelligent ...

START will leverage Trialing’s platform to distribute curated information on ongoing early-phase oncology trials.

POTOMAC, MD / ACCESS Newswire / March 18, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, ...

PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...